

07/16/2008

10-589,051-2.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajem1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEMLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPLUS and USPAT databases updated with IPC

reclassification data
NEWS 30 JUN 30 AEROSPACE enhanced with more than 1 million U.S.
patent records
NEWS 31 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
options to display authors and affiliated
organizations
NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist
Assistant and BLAST plug-in
NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:53:03 ON 16 JUL 2008

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:53:14 ON 16 JUL 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUL 2008 HIGHEST RN 1034171-01-1

DICTIONARY FILE UPDATES: 15 JUL 2008 HIGHEST RN 1034171-01-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:


07/16/2008

10-589,051-2.trn

<http://www.cas.org/support/stngen/stdoc/properties.html>

 \Rightarrow

Uploading C:\Program Files\Stnexp\Queries\10-533,555-2.str



```
chain nodes :
```

10 11 13 14

```

ring nodes :

```

1 2 3 4 5 6 7 8 9 12 15 16 17 18

chain bonds :

7-10 8-11 10-12 10-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-15 12-18 15-16 16-17 17-18

exact/norm bonds :

5-7 6-9 7-8 7-10 8-9 8-11 10-13 12-15 12-18 15-16 16-17 17-18

exact bonds :

10-12

```
normalized bonds :
```

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

```
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
```

```
11:CLASS 12:Atom 13:Atom 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
```

L1 STRUCTURE UPLOADED


$$\Rightarrow d \mid 11$$

L1 HAS NO ANSWERS

L1	STR
----	-----

07/16/2008

10-589,051-2.trn



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:53:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 108 TO ITERATE

100.0% PROCESSED 108 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1537 TO 2783

PROJECTED ANSWERS: 6 TO 266

L2 6 SEA SSS SAM L1


=> d scan

07/16/2008

10-589,051-2.trn

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one,
5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-
1H-benzimidazol-2-yl)phenylmethylene]-, (3Z)-
MF C30 H31 N5 O2

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylene]-5-
[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)-
MF C29 H27 F2 N5 O

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-methoxyphenyl)methylene]-5-[(1-
ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)-
MF C30 H31 N5 O2

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 3-[(2,4-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-
ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)-
MF C25 H25 F2 N5 O

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

07/16/2008

10-589,051-2.trn

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(2-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)-
MF C26 H28 F N5 O

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Indol-2-one, 1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)phenylmethylene]-5-[[1-(phenylmethyl)-3-pyrrolidinyl]amino]-, (3Z)-
MF C34 H31 N5 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

07/16/2008

10-589,051-2.trn

=> s l1 sss full
FULL SEARCH INITIATED 14:54:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1991 TO ITERATE

100.0% PROCESSED 1991 ITERATIONS 109 ANSWERS
SEARCH TIME: 00.00.01

L3 109 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 178.82 179.03

FILE 'CAPLUS' ENTERED AT 14:54:36 ON 16 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2008 VOL 149 ISS 3
FILE LAST UPDATED: 15 Jul 2008 (20080715/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3
L4 2 L3

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

07/16/2008

10-589,051-2.trn

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:33844 CAPLUS
DOCUMENT NUMBER: 146:119982
TITLE: A subtype of non-small cell lung carcinoma (NSCLC) tumors dependent on platelet-derived growth factor receptor α and its diagnosis and treatment
INVENTOR(S): Rikova, Klarisa; Polakiewicz, Roberto; Guo, Ailan; Crosby, Katherine; Zeng, Qingfu; Lee, Kimberly
PATENT ASSIGNEE(S): Cell Signaling Technology, Inc., USA
SOURCE: PCT Int. Appl., 98pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007005027	A1	20070111	WO 2005-US23858	20050705
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070148711	A1	20070628	US 2005-174051	20050701
AU 2005334101	A1	20070111	AU 2005-334101	20050705
CA 2617201	A1	20070111	CA 2005-2617201	20050705
EP 1907842	A1	20080409	EP 2005-768977	20050705
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
KR 2008030648	A	20080404	KR 2008-702716	20080131
PRIORITY APPLN. INFO.:			US 2005-174051	A 20050701
			WO 2005-US23858	W 20050705

AB A previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor α drives the disease is identified. The receptor can be used as a marker to identify these tumors and as a target for cancer chemotherapy using PDGFR α -inhibiting drugs. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR α is expressed, and for determining whether a compound inhibits the progression of a PDGFR α -expressing mammalian NSCLC tumor. PDGFR α was identified as extensively phosphorylated in NSCLC cell lines. Immunoassays showed that the receptor was present in H1703 cells, but not in A549 cells. H1703 cells were sensitive to inhibition of the protein tyrosine kinase inhibitor Gleevec. A survey of patients showed

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:493723 CAPLUS
DOCUMENT NUMBER: 141:54195
TITLE: Preparation of oxindole derivatives as kinase modulators
INVENTOR(S): Bannan, Lynne Canne; Brown, S. David; Cheng, Wei; Co, Erick Wang; Nuss, John M.; Kim, Moon Hwan; Klein, Rhett Ronald; Le, Donna T.; Lew, Amy; Mac, Morrison B.; Parks, Jason Jevious; Wen, Zhaoyang; Xu, Wei
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050681	A2	20040617	WO 2003-US36567	20031114
WO 2004050681	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506546	A1	20040617	CA 2003-2506546	20031114
AU 2003302665	A1	20040623	AU 2003-302665	20031114
EP 1581309	A2	20051005	EP 2003-812437	20031114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006510727	T	20060330	JP 2004-570758	20031114
US 20060122171	A1	20060608	US 2005-533555	20050502
PRIORITY APPLN. INFO.:			US 2002-426680P	P 20021115
			US 2003-470674P	P 20030514
			WO 2003-US36567	W 20031114

OTHER SOURCE(S): MARPAT 141:54195

GI



L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

that PDGFR α was present in 6% of NSCLC cases.
IT 918312-08-0
RI: THU (Therapeutic use); BICL (Biological study); USES (Uses) (for inhibition of growth of PDGFR α -dependent NSCLC; subtype of NSCLC tumors dependent on PDGFR α and its diagnosis and treatment)
RN 918312-08-0 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluorophenyl)-(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB The title compds. I [W = N or CR1; R1 = H, halo, trihaloalkyl, CN, NH2, NO2, OR6, N=CNR6R7, N(R6)C(=NR8)NR6R7, SR6, S(O)1-2R6, SO2NR6R7, CO2R6, etc.; L = O, S(O)0-2, or NR3; Q = C or N, when Q = N, then R4 does not exist; R2, R3 = H or R7; R4, R5 = H, OR6, NR6R7, S(O)0-2R6, SO2NR6R7, CO2R6, C(O)NR6R7, N(R6)SO2R6, NC(O)2R6, C(O)R7, CN, NO2, NH2, halo, trihaloalkyl, R7; or R4, R5 when taken together, form a five or six-membered aromatic ring containing 0-2 N; R6, R7 = H, (substituted)arylalkyl, (substituted)heterocyclylalkyl, (substituted)aryl, (substituted)heterocyclyl, with proviso or R6, R7 = when taken together with a common N to which they are attached, form a five to seven-membered heterocyclic ring containing at least one addnl. heteroatom selected from N, O, S, or P; R8 = H, NO2, CN, OR6, or (substituted)alkyl; X = (substituted)heteroaromatic ring; K = O, S, (substituted)amino] were prepared as kinase modulators to treat kinase-dependent diseases and conditions. For example compound II was prepared in a multi-step synthesis starting from 4-methylimidazole. The latter inhibited KDR and EGFR with IC50 < 50 nM.

IT 705945-78-4P 705945-79-5P 705945-80-8P
705945-81-9P 705945-82-0P 705945-83-1P
705945-84-2P 705945-85-3P 705945-86-4P
705945-87-5P 705945-88-6P 705945-89-7P
705945-90-0P 705945-92-2P 705945-93-3P
705945-94-4P 705945-95-5P 705945-96-6P
705945-97-7P 705945-98-8P 705945-99-9P
705946-00-5P 705946-01-6P 705946-02-7P
705946-03-8P 705946-04-9P 705946-05-0P
705946-06-1P 705946-07-2P 705946-14-1P
705946-15-2P 705946-16-3P 705946-17-4P
705946-18-5P 705946-19-6P 705946-21-0P
705946-22-1P 705946-23-2P 705946-24-3P

07/16/2008

10-589,051-2.trn

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


705946-25-4P 705946-26-5P 705946-27-6P
 705946-28-7P 705946-29-8P 705946-30-1P
 705946-31-2P 705946-32-3P 705946-33-4P
 705946-34-5P 705946-35-6P 705946-36-7P
 705946-37-8P 705946-38-9P 705946-39-0P
 705946-40-3P 705946-41-4P 705946-42-5P
 705946-43-6P 705946-44-7P 705946-45-8P
 705946-46-9P 705946-47-0P 705946-48-1P
 705946-49-2P 705946-50-5P 705946-51-6P
 705946-52-7P 705946-53-8P 705946-54-9P
 705946-55-0P 705946-56-1P 705946-57-2P
 705946-58-3P 705946-59-4P 705946-60-7P
 705946-61-8P 705946-62-9P 705946-64-1P
 705946-65-2P 705946-66-3P 705946-67-4P
 705946-68-5P 705946-69-6P 705946-70-9P
 705946-71-0P 705946-72-1P 705946-73-2P
 705946-74-3P 705946-76-5P 705946-77-6P
 705946-78-7P 705946-79-8P 705946-80-1P
 705946-81-2P 705946-82-3P 705946-83-4P
 705946-84-5P 705946-85-6P 705946-86-7P
 705946-87-8P 705946-88-9P 705946-89-0P
 705946-90-3P 705946-91-4P 705946-92-5P
 705946-93-6P 705946-94-7P 706816-70-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of oxindole derivs. as kinase modulators)

RN 705945-78-4 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)phenylmethylene]-5-[1-(phenylmethyl)-3-pyrrolidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705945-79-5 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-3-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)phenylmethylene]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705945-83-1 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)(4-methylphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-84-2 CAPLUS
 CN 2H-Indol-2-one, 3-[(1H-benzimidazol-2-yl)(4-nitrophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705945-85-3 CAPLUS
 CN 2H-Indol-2-one, 3-[(1H-benzimidazol-2-yl)(4-methoxyphenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705945-80-8 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)phenylmethylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-81-9 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(1H-benzimidazol-2-yl)phenylmethylene]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705945-82-0 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)(4-methoxyphenyl)methylene]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705945-86-4 CAPLUS
 CN 2H-Indol-2-one, 3-[(1H-benzimidazol-2-yl)phenylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705945-87-5 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-[(6-methoxy-1H-benzimidazol-2-yl)phenylmethylene]-5-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-88-6 CAPLUS
 CN 2H-Indol-2-one, 3-[(4-aminophenyl)-1H-benzimidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




07/16/2008

10-589,051-2.trn

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 705945-89-7 CAPLUS
 CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-methylphenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-90-0 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-imidazol-2-yl(4-methylphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705945-92-2 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-imidazol-2-yl(4-methoxyphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705945-96-6 CAPLUS
 CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3-nitrophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705945-97-7 CAPLUS
 CN Benzonitrile, 3-[(Z)-1H-benzimidazol-2-yl[5-[(1-ethyl-4-piperidinyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 705945-98-8 CAPLUS
 CN 2H-Indol-2-one, 3-[(3-aminophenyl)-1H-benzimidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705945-93-3 CAPLUS
 CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705945-94-4 CAPLUS
 CN 2H-Indol-2-one, 3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705945-95-5 CAPLUS

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705945-99-9 CAPLUS
 CN 2H-Indol-2-one, 3-(1H-benzimidazol-2-ylphenylmethylene)-1,3-dihydro-5-(4-piperidinylamino)-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-00-5 CAPLUS
 CN Benzenecarboximidamide, 3-[(Z)-1H-benzimidazol-2-yl[5-[(1-ethyl-4-piperidinyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-01-6 CAPLUS
 CN 2H-Indol-2-one, 3-(1H-benzimidazol-2-ylphenylmethylene)-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



07/16/2008


10-589,051-2.trn

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 705946-02-7 CAPLUS

CN 2H-Indol-2-one, 3-([1H-benzimidazol-2-ylphenylmethylene]-1,3-dihydro-5-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-03-8 CAPLUS

CN 2H-Indol-2-one, 3-([1H-benzimidazol-2-yl(3-methoxyphenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-04-9 CAPLUS

CN 2H-Indol-2-one, 3-([1H-benzimidazol-2-yl(3-chlorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-05-0 CAPLUS

CN 1H-Indole-1,3(2H)-dione, 2-[2-[(Z)-[5-[(1-ethyl-4-piperidinyl)amino]-

1,2-dihydro-2-oxo-3H-indol-3-ylidene]phenylmethyl]-1H-imidazol-5-yl]ethyl]-


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-15-2 CAPLUS

CN 2H-Indol-2-one, 3-([1H-benzimidazol-2-yl(3-methoxyphenyl)methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-16-3 CAPLUS

CN 2H-Indol-2-one, 3-[(3-chlorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-17-4 CAPLUS

CN 2H-Indol-2-one, 3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Double bond geometry as shown.



RN 705946-06-1 CAPLUS

CN 2H-Indol-2-one, 3-([1H-benzimidazol-2-ylphenylmethylene)-5-[[1-(2-(dimethylamino)ethyl)-4-piperidinyl]amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-07-2 CAPLUS

CN 2H-Indol-2-one, 3-([1H-benzimidazol-2-ylphenylmethylene)-1,3-dihydro-5-[[1-(methylsulfonyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-14-1 CAPLUS

CN 2H-Indol-2-one, 3-([1H-benzimidazol-2-yl(3-chlorophenyl)methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-18-5 CAPLUS

CN 2H-Indol-2-one, 3-([1H-benzimidazol-2-yl(3,5-difluorophenyl)methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-19-6 CAPLUS

CN 2H-Indol-2-one, 3-([1H-benzimidazol-2-yl(3-chlorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)methylamino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-21-0 CAPLUS


CN 2H-Indol-2-one, 3-([1H-benzimidazol-2-yl(4-chlorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

07/16/2008


10-589,051-2.trn

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705946-22-1 CAPLUS
CN 2H-Indol-2-one, 3-[(1H-benzimidazol-2-yl(3-fluorophenyl)methylene)-1,3-dihydro-5-[(1-(2-methoxyethyl)-4-piperidinyl)amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-23-2 CAPLUS
CN 2H-Indol-2-one, 3-[(1H-benzimidazol-2-yl(4-fluorophenyl)methylene)-1,3-dihydro-5-[(1-(2-methoxyethyl)-4-piperidinyl)amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-24-3 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chlorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 705946-27-6 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluorophenyl)-(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-28-7 CAPLUS
CN 2H-Indol-2-one, 3-[(1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylene)-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-29-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chloro-4-fluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705946-25-4 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-26-5 CAPLUS
CN 2H-Indol-2-one, 3-[(1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylene)-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705946-30-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-31-2 CAPLUS
CN 2H-Indol-2-one, 3-[(6-chloro-1H-benzimidazol-2-yl)phenylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-32-3 CAPLUS
CN 2H-Indol-2-one, 3-[(6-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

07/16/2008

10-589,051-2.trn


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Double bond geometry as shown.



RN 705946-33-4 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluoro-4-methylphenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-34-5 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(4-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705946-37-8 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)-6-fluoro-1H-benzimidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 705946-38-9 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)-6-fluoro-1H-benzimidazol-2-ylmethylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-35-6 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-imidazol-2-yl(4-propylphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-36-7 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-imidazol-2-yl(4-(trifluoromethyl)phenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 705946-39-0 CAPLUS
 CN 2H-Indol-2-one, 3-[(3-fluoro-4-methylphenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-40-3 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(5-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-41-4 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluoro-4-(trifluoromethyl)phenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

07/16/2008


10-589,051-2.trn

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-42-5 CAPLUS
 CN 2H-Indol-2-one,
 3-[(4-chlorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-ethyl-
 4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-43-6 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluoro-4-
 methylphenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)-
 (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-44-7 CAPLUS
 CN 2H-Indol-2-one,
 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(5-methyl-
 1H-imidazol-2-yl)[6-(trifluoromethyl)-3-pyridinyl]methylene]-, (3Z)- (CA
 INDEX NAME)


Double bond geometry as shown.



RN 705946-45-8 CAPLUS
 CN 2H-Indol-2-one,
 1,3-dihydro-3-[(1H-imidazol-2-yl)(4-methylphenyl)methylene]-
 5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-46-9 CAPLUS
 CN 2H-Indol-2-one, 3-[(3-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-
 1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA
 INDEX NAME)


Double bond geometry as shown.



RN 705946-47-0 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-[(1H-imidazol-2-yl)[4-
 (trifluoromethyl)phenyl]methylene]-5-[[1-(2-methoxyethyl)-4-
 piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705946-48-1 CAPLUS
 CN 2H-Indol-2-one, 3-[(6-chloro-1H-benzimidazol-2-yl)phenylmethylene]-1,3-
 dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX
 NAME)

Double bond geometry as shown.



RN 705946-49-2 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)-1H-imidazol-2-ylmethylene]-5-[(1-
 ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-50-5 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)(5-methyl-1H-imidazol-2-
 yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA
 INDEX NAME)

07/16/2008


10-589,051-2.trn

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Double bond geometry as shown.



RN 705946-51-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-52-7 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)-5-methyl-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-53-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-3-[[5-methyl-1H-imidazol-2-yl](4-methylphenyl)methylene]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-54-9 CAPLUS
CN 2H-Indol-2-one, 3-[(4-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-55-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-difluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-56-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chloro-4-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-57-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-58-3 CAPLUS
CN 2H-Indol-2-one, 3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

07/16/2008


10-589,051-2.trn

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-59-4 CAPLUS
CN 2H-Indol-2-one,
3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
5-[[1-[2-(4-morpholinyl)ethyl]-4-piperidinyl]amino]-, (3Z)- (CA INDEX
NAME)


Double bond geometry as shown.



RN 705946-60-7 CAPLUS
CN 2H-Indol-2-one, 5-[[1-[2-(diethylamino)ethyl]-4-piperidinyl]amino]-3-[(3-
fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX
NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705946-64-1 CAPLUS
CN 1H-Imidazole-5-carboxylic acid,
2-[(Z)-[1,2-dihydro-5-[[1-(2-methoxyethyl)-
4-piperidinyl]amino]-2-oxo-3H-indol-3-ylidene](3-fluorophenyl)methyl]-4-
methyl-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-65-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(1H-imidazol-2-ylphenyl)methylene]-5-[[1-(2-
methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-66-3 CAPLUS
CN 2H-Indol-2-one,
1,3-dihydro-3-[[1H-imidazol-2-yl(4-methoxyphenyl)methylene]-

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-61-8 CAPLUS
CN 2H-Indol-2-one,
3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
5-[[1-[2-(1-pyrrolidinyl)ethyl]-4-piperidinyl]amino]-, (3Z)- (CA INDEX
NAME)

Double bond geometry as shown.




RN 705946-62-9 CAPLUS
CN 2H-Indol-2-one,
1,3-dihydro-3-[[1H-imidazol-2-yl(4-methylphenyl)methylene]-
5-[[1-(1-methyl-4-piperidinyl)amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-67-4 CAPLUS
CN 2H-Indol-2-one,
3-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-68-5 CAPLUS
CN 2H-Indol-2-one, 3-[[1-[2-(4-chlorophenyl)methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

07/16/2008


10-589,051-2.trn

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-69-6 CAPLUS
CN 2H-Indol-2-one,
3-[(3-fluorophenyl)-1H-imidazol-2-ylmethylene]-1,3-dihydro-
5-[[1-(methylsulfonyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-70-9 CAPLUS
CN 2H-Indol-2-one,
1,3-dihydro-3-[1H-imidazol-2-yl(4-propylphenyl)methylene]-
5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-73-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3-fluoro-4-methylphenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-74-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[1H-imidazol-2-yl[6-(trifluoromethyl)-3-pyridinyl]methylene]-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-71-0 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(3-fluorophenyl)(5-phenyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-72-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3-fluorophenyl)(5-phenyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-5-[[1-(2-methoxyethyl)-4-piperidinyl]amino]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-76-5 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl]-1H-imidazol-2-ylmethylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-77-6 CAPLUS
CN 2H-Indol-2-one,
5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(5-methyl-1H-imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

07/16/2008


10-589,051-2.trn

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-78-7 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chlorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-79-8 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 705946-82-3 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(4-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-83-4 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(2-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-80-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-difluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-81-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chloro-4-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 705946-84-5 CAPLUS
CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 705946-85-6 CAPLUS
CN 2H-Indol-2-one, 3-[(2,3-difluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-86-7 CAPLUS
CN 2H-Indol-2-one, 3-[(2,3-difluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

07/16/2008


10-589,051-2.trn

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-87-8 CAPLUS
 CN 2H-Indol-2-one, 3-[(2,4-difluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-88-9 CAPLUS
 CN 2H-Indol-2-one, 3-[(2,4-difluorophenyl)(1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-89-0 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-3-[(2-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-90-3 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[1H-imidazol-2-yl][3-(trifluoromethyl)phenyl]methylene-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-91-4 CAPLUS
 CN 2H-Indol-2-one, 5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-3-[(5-methyl-1H-imidazol-2-yl)[3-(trifluoromethyl)phenyl]methylene]-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 705946-92-5 CAPLUS
 CN 2H-Indol-2-one, 3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 705946-93-6 CAPLUS
 CN 2H-Indol-2-one, 3-[(2,4-dichloro-5-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 705946-94-7 CAPLUS
 CN 2H-Indol-2-one, 3-[(4-chloro-2-fluorophenyl)(5-methyl-1H-imidazol-2-yl)methylene]-5-[(1-ethyl-4-piperidinyl)amino]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

10-589,051-2.trn

CC1CCN(CC1)NC2=CC=C3C(=C2)C(=O)N3C(=O)C4=C(C5=CC=C(C=C5)C(F)=CC=C5C1)C6=NC(=C)N(C)C6

Double bond geometry as shown.



07/16/2008

10-589,051-2.trn

=>